NO943101L - 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist - Google Patents

2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Info

Publication number
NO943101L
NO943101L NO943101A NO943101A NO943101L NO 943101 L NO943101 L NO 943101L NO 943101 A NO943101 A NO 943101A NO 943101 A NO943101 A NO 943101A NO 943101 L NO943101 L NO 943101L
Authority
NO
Norway
Prior art keywords
treatment
methano
receptor antagonist
quinolizine derivative
hallucinatory
Prior art date
Application number
NO943101A
Other languages
English (en)
Other versions
NO943101D0 (no
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO943101D0 publication Critical patent/NO943101D0/no
Publication of NO943101L publication Critical patent/NO943101L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen angår 5-klor-2,3-dihydro-2,2-dimetylbenzofuran-7-karboksylsyre-oktahydro-3-hydroksy-2,6-metano-2H-kinolizin-8-ylester (I),. en ny 5-HT-reseptorantagonist, dens fremstillingsmetode og dens sluttelige anvendelse ved behandling av radio- og kjemo-terapeutisk-fremkalt kvalme og brekninger, ved behandling av smerte assosiert med migrene, ved behandling av erkjennelsessykdommer, ved behandling av hallusinatoriske, endogene psy-koser av den type som manifesteres i pasienter som lider av schizofreni og mani, for irritabel tarmsyndrom, og for å bekjempe legemiddelmisbruk.
NO943101A 1992-02-24 1994-08-23 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist NO943101L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24
PCT/US1993/000880 WO1993017019A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Publications (2)

Publication Number Publication Date
NO943101D0 NO943101D0 (no) 1994-08-23
NO943101L true NO943101L (no) 1994-08-23

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943101A NO943101L (no) 1992-02-24 1994-08-23 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist

Country Status (14)

Country Link
EP (1) EP0628043A1 (no)
JP (1) JPH07504192A (no)
KR (1) KR100287933B1 (no)
AU (1) AU675060B2 (no)
CA (1) CA2130563C (no)
FI (1) FI105917B (no)
HU (1) HU216831B (no)
IL (1) IL104821A (no)
MX (1) MX9300948A (no)
NO (1) NO943101L (no)
NZ (1) NZ249346A (no)
TW (1) TW226374B (no)
WO (1) WO1993017019A1 (no)
ZA (1) ZA931146B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537255A (ja) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト リウマチ性炎症性プロセスに対する５−ｈｔ３レセプターアンタゴニストの全身的使用
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329932B1 (en) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
MX9300948A (es) 1993-08-01
CA2130563C (en) 1997-11-11
HUT68249A (en) 1995-06-28
HU9402436D0 (en) 1994-10-28
EP0628043A1 (en) 1994-12-14
WO1993017019A1 (en) 1993-09-02
NO943101D0 (no) 1994-08-23
NZ249346A (en) 1995-10-26
JPH07504192A (ja) 1995-05-11
HU216831B (hu) 1999-09-28
TW226374B (no) 1994-07-11
AU675060B2 (en) 1997-01-23
FI943872A (fi) 1994-08-23
FI943872A0 (fi) 1994-08-23
KR100287933B1 (ko) 2001-05-02
FI105917B (fi) 2000-10-31
CA2130563A1 (en) 1993-09-02
AU3603493A (en) 1993-09-13
IL104821A0 (en) 1993-06-10
ZA931146B (en) 1993-09-14
KR950700297A (ko) 1995-01-16
IL104821A (en) 1997-01-10

Similar Documents

Publication Publication Date Title
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
TW200505901A (en) Muscarinic agonists
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
MA28021A1 (fr) Dérivés de benzimidazolone à activité agoniste des récepteurs 5-HT4
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
DE69818678D1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
DK1276476T3 (da) Anvendelse af bradykardiske midler ved behandling af sygdomme i hjertemuskulaturen i forbindelse med hypertrofi, samt hedtil ukendte lægemiddelkombinationer
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
NO943101L (no) 2,6-metano-2H-kinolizinderivat som 5-HT3-reseptorantagonist
NO991194L (no) Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid
EA200400302A1 (ru) Способ лечения первичной бессонницы
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
MXPA02006146A (es) Uso de metabolitos bioactivos de gepirona para el tratamiento de desordenes psicologicos.
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
Glasper et al. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
NO951865L (no) Quinuclidin-derivat som substans-P antagonist
Ansseau et al. The use of high dose lormetazepam in psychiatric in-patients
RU2001101468A (ru) Применение оптически чистого (-)норцисаприда для лечения апноэ, булимии и других расстройств